When the Breakthrough Obesity G-Agonist Drugs Exceed Expectations The expanding GLP-1 family of drugs and their expanded potential use cases Back last December I wrote about the The New Obesity Breakthrough Drugs, and specifically the striking results in randomized trials for semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight loss, their putative mechanism(s), while also emphasizing their very high cost, lack of plan for successful weaning, and exacerbation of health inequities
Kontogianni MD, Dafni UG, Routsias JG, Skopouli FN
Also, remember that as with other supplements, side effects may occur
In the ovaries of healthy women most (99%) of inositol is myo-inositol
Organizations sourcing peptides in larger quantities frequently seek suppliers that can provide dependable support as purchasing requirements evolve
A program launched this week by HealthEquity, a health savings account and consumer-directed benefits administrator, connect its 10 million HSA members to GLP-1 medications, both brand name and less-costly compounded dosages, through Agile Telehealth